CEL-SCI CORPORATION Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
CEL-SCI CORPORATION (CVM) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of $760.64 thousand for the 12-month period ending 2019-09-30, per its 10-K/A filed 2019-12-23.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2019-12-23
- CEL-SCI CORPORATION fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2019 was $760.64K, a 90.36% decline from fiscal 2018.
- CEL-SCI CORPORATION fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2018 was $7.89M.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|
| 2019-09-30 | $760.64K 10-K/A · filed 2019-12-23 |
| 2018-09-30 | $7.89M 10-K/A · filed 2019-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |